Anti-CD24 nano-targeted delivery of docetaxel for the treatment of prostate cancer

详细信息    查看全文

• 作者：Dhruba J. Bharali ; PhD^a ; ¹ ; Thangirala Sudha ; PhD^a ; ¹ ; Huadong Cui ; PhD ; MD^a ; ² ; Badar M. Mian ; MD^b ; Shaker A. Mousa ; PhD^a ; ^{shaker.mousa@acphs.edu}
• 关键词：Anti-CD24 ; Docetaxel ; PLGA nanoparticle ; Prostate cancer ; Targeted therapy
• 刊名：Nanomedicine: Nanotechnology, Biology and Medicine
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：13
• 期：1
• 页码：263-273
• 全文大小：1401 K
• 卷排序：13

文摘

Nanoparticle (NP)-mediated, noninvasively targeted and image-guided therapies have potential to improve efficacy and safety of cancer therapeutics. We report synthesis and use of poly(lactide-co-glycolide)-polyethylene glycol (PLGA-PEG) NPs for targeted delivery of docetaxel. We synthesized docetaxel encapsulated NPs conjugated to anti-CD24 (for targeting) and/or an optical probe (for tracking) and evaluated efficacy in a prostate cancer mouse model. We observed preferential accumulation of anti-CD24 conjugated NPs (encapsulating docetaxel) compared to the non-conjugated NPs 24 hours after a single injection into luciferase-expressing PC3M prostate cancer tumor. In the same mouse model, we found significant (P < 0.01) accumulation of docetaxel (~10-fold higher) in tumor after treatment with PLGA-PEG NPs encapsulating docetaxel and conjugated to anti-CD24 compared to non-conjugated NPs. Enhanced accumulation was associated with reduced tumor mass and tumor viability. These data support the potential impact of nano-targeted delivery of chemotherapy in enhancing the differential tumor delivery and anticancer efficacy in prostate cancer.